


































An evaluation of Drosophila as a model system for studying tauopathies
such as Alzheimer's disease
Sivanantharajah, Lovesha; Mudher, Amritpal; Shepherd, David





Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Sivanantharajah, L., Mudher, A., & Shepherd, D. (2019). An evaluation of Drosophila as a model
system for studying tauopathies such as Alzheimer's disease. Journal of Neuroscience Methods,
319(May), 77-88. https://doi.org/10.1016/j.jneumeth.2019.01.001
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.




















1 School of Natural Sciences, Bangor University, Bangor, Gwynedd, UK 










Work spanning almost two decades using the fruit fly, Drosophila melanogaster, to study 
tau-mediated neurodegeneration has provided valuable and novel insights into the causes 
and mechanisms of tau-mediated toxicity and dysfunction in tauopathies such as 
Alzheimer’s Disease (AD). The fly has proven to be an excellent model for human diseases 
because of its cost efficiency, and the availability of powerful genetic tools for use in a 
comparatively less-complicated, but evolutionarily conserved, in vivo system. In this review, 
we provide a critical evaluation of the insights provided by fly models, highlighting both the 
advantages and limitations of the system. The fly has contributed to a greater 
understanding of the causes of tau abnormalities, the role of these abnormalities in 
mediating toxicity and/or dysfunction, and the nature of causative species mediating tau-
toxicity. However, it is not possible to perfectly model all aspects of human degenerative 
diseases.  What sets the fly apart from other animal models is its genetic tractability, which 
makes it highly amenable to overcoming experimental limitations. The explosion of genetic 
technology since the first fly disease models were established has translated into fly lines 
that allow for greater temporal control in restricting tau expression to single neuron types, 
and lines that can label and monitor the function of subcellular structures and components; 
thus, fly models offer an unprecedented view of the neurodegenerative process. Emerging 
genetic technology means that the fly provides an ever-evolving experimental platform for 
studying disease.   
 
 




1.1 Is the fly a good model to study neurodegeneration? 
The first Drosophila models analysing the effects of human tau (htau) on the fly 
nervous system stemmed from work by Williams et al. (2000) and Wittman et al. (2001). 
Williams et al. (2000) showed that expression of a variety of tau fusion proteins, including 
htau or bovine tau, in adult sensory neurons produced morphological phenotypes such as 
axon blebbing, axon loss, axon defasciculation, and reduced arborization that were 
consistent with a degenerative process. Wittman et al. (2001) subsequently showed that 
expression of wild type and mutant tau proteins had a significant effect on longevity with an 
obvious neurodegenerative outcome that was more pronounced with disease-causing 
mutant tau proteins. These two studies were the earliest to document the 
neurodegenerative effects of tau overexpression in fly neurons, which appeared to 
recapitulate disease pathology phenotypes observed in tauopathies like Alzheimer’s 
disease (AD). Coupled with the demonstration that neurodegeneration associated with 
other neurodegenerative diseases, such as Parkinson’s disease (Feany and Bender 2000) 
and Huntington’s disease (Jackson et al. 1998), could be simulated in flies, Drosophila was 
established as a credible animal model for studying the cellular and molecular mechanisms 
of human diseases. Building on these studies the use of Drosophila as a disease model has 
expanded rapidly and played an important role in furthering our understanding of the role of 
tau in pathogenesis and progression of AD, and other tauopathies.   
 
1.1.1 Deep evolutionary conservation 
At a superficial level the fly may not seem an obvious model for studying human 
neurogenerative diseases, but closer examination of shared biology reveals more 
similarities than differences with humans. There is a large body of evidence demonstrating 
a deep evolutionary conservation in animal nervous systems, and the Drosophila and 
human nervous systems show a remarkable degree of molecular and cellular conservation.  
Fundamental developmental processes and principles used by both flies and humans to 
build a complex nervous system descended from a shared common ancestor that lived 
roughly 570 million years ago. This ancestor was already equipped with a fully functioning 
nervous system with all the elements that we would recognise today (Denes et al. 2007), 
consequently, flies and humans share similar neuron morphology, physiology, transmitter 
systems, cell biology and neurochemistry. 
 
At the cellular level, all the cellular machinery of mammalian neurons is conserved in 
flies with homologous proteins and processes underlying the structure of the cytoskeleton, 
axon transport processes, synaptic transmission, neuron excitability, and signal 
transduction. These homologies are not just restricted to cellular components, at the 
molecular level many fundamental genetic programs that lay the body plan and dictate how 
the nervous system is built are conserved. For example, differentiation and determination of 
neuronal identity is controlled by the same conserved family of transcription factors, the 
Homeotic selector (Hox) genes, that pattern neuronal identity (i.e. establish different neuron 
subtypes) along the anterior-posterior body axis in both flies and humans (reviewed by 
Philippidou and Dasen 2013).   
 
Despite the cellular and molecular homologies, mammalian and insect nervous 
systems are often seen as being fundamentally different in the way in which they are 
organised and assembled during development; however, even here there is increasing 
evidence that aspects of brain organisation and development are also conserved. This 
ranges from the mechanisms that specify the neuroaxis and the development of the 
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different brain regions (Arendt et al. 2008, 2016, Denes et al. 2007) to the way in which 
neurons are generated. In both flies and mammals, neurons are organised into functionally 
specialized groups, with similar functional roles and properties, sharing the same 
developmental origins. The stem cells generating the pools of functionally similar 
interneurons in the vertebrate spinal cord appear to be conserved with the progenitor cells 
and transcription factors that define different interneuron classes conserved from lower 
vertebrates to mammals (Lupo et al. 2006) and insects (Lacin and Truman 2016, Harris et 
al. 2015).  Perhaps more controversial, there is evidence that the structure of the nervous 
system may also be conserved with growing evidence of homology between structures in 
the fly and mammalian brains with conserved roles, one example being brain regions 
associated with learning and memory (Wolff and Strausfeld 2016). 
 
In summary, this level of evolutionary conservation is important because it allows 
more accurate modelling of pathways that can contribute to disease pathogenesis and 
progression. Though cellular environments between flies and humans may be not be 
identical, they are certainly similar enough to allow modelling of human disease in a 
comparatively simple animal.  
 
1.1.2 Comparative simplicity  
The fundamental feature of the fly that gives it such utility as a model for human 
diseases such as AD, is the conservation of disease related genes.  It has long been known 
that 75% of the human genes known to be associated with neurological conditions have 
orthologues in flies (Bier 2005). Given the relative simplicity of the fly genome compared to 
the human genome, which has a high level of functional genetic redundancy, the function of 
novel disease related genes can be more easily dissected and understood in the fly. Where 
in humans and rodents there are often multiple isoforms of the proteins associated with 
disease, in flies there are often fewer isoforms.  How true this is for tau is not entirely clear, 
because though numerous tau-like polypeptides are predicted in flybase 
(http://flybase.org/reports/FBgn0266579) there is evidence verifying just one primary 
isoform and suggesting another larger isoform present at much lower levels (Heidary and 
Fortini 2001, Burnouf et al. 2016).  Nonetheless, this is still fewer than those found in 
vertebrates: three isoforms identified in rodents (Mavilia et al. 1993) and six isoforms 
expressed in the central nervous system (CNS) of humans (Ksiezak-Reding et al.1988).  
Less genetic redundancy in flies means that one is less likely to see compensatory effects 
of multiple isoforms when studying the role of any one isoform in disease using fly models. 
Comparative simplicity also extends to the nervous system, which in adult flies is composed 
of roughly 100,000 neurons. This has already contributed to detailed connectivity maps of 
fly neurons with single-cell resolution (Takemura et al. 2017a, Takemura et al. 2017b).  
Soon it will be possible to examine the effects of pathogenic proteins at the level of an 
individual neuron and its connections or even on a larger scale—an entire connectome.  
  
1.1.3 Experimental tractability 
An advantage of the fly as an experimental system is that it is not limited by some of the 
considerations that affect mammalian systems, such as costs, care and time.  Cell culture 
models can offer a cost-effective alternative to rodent models, but they are limited for 
probing behaviour and systems-level responses. Advancement with organoids will 
undoubtedly present better solutions for recreating a multicellular environment to study 
disease, but organoids are still in vitro models and have some of the limitations of standard 
cell culture techniques.  In contrast to this, the fly is an inexpensive, time-efficient, 
genetically tractable model that permits detailed, in vivo dissection of the mechanisms 
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underpinning pathogenesis and progression of disease, whilst permitting impact on 
behavioural outputs. Furthermore, the genetic tool kit available in the fly gives it a value that 
is hard to parallel in any other multicellular system with a complex central brain.  In flies it is 
possible to model many facets of tau pathology in vivo, such as cell death and tau 
hyperphosphorylation. It is also possible to study how these pathologies influence complex 
behaviours affected in human disease, such as memory dysfunction, circadian behaviour, 
and locomotor function using standardized and well-characterised behavioural assays 
(Ugur et al. 2016).  Nonetheless, not all pathological aspects of disease can be emulated in 
flies, though sometimes this may itself prove informative. For example, some disease 
elements like the formation of insoluble, tau aggregates and tangles are not observed in 
flies (except in particular experimental scenarios discussed later). While this might seem to 
be a limitation of the fly it may in fact be revealing, suggesting that tau aggregation per se is 
not necessary for tau-mediated toxicity and dysfunction, since these fly models display 
neurodegeneration even in the absence of tau aggregation. Rather, these models imply that 
aggregation could be a late stage or end stage pathology. Indeed, this is now reiterated by 
numerous rodent models as well (reviewed in Cowan and Mudher 2013).  
A key consideration when assessing the value of the fly, or any other model, is to 
understand how each model is suited to addressing particular questions rather than how 
accurately it emulates human disease. For example, expressing tau in motor neurons of 
larval Drosophila creates a locomotor phenotype, which in itself may not be relevant to AD 
(even though it is a feature of many other tauopathies). However, by expressing tau 
specifically in motor neurons it is possible to ask how abnormal tau disrupts neuronal 
function in a neuronal circuit that is ideal for probing neuronal structure and functional 
defects (e.g. using axonal transport and synaptic integrity assays)(Chee et al. 2005), which 
culminate in a quantifiable behavioural output (e.g. locomotor assays) (Mudher et al. 2004).  
This information may be extrapolated to shed light on how neuronal function may be altered 
by pathological tau in other circuits affected in tauopathies.  
 
As with all other models of disease, there are some elements of disease that simply 
cannot be modelled in a fly due to different life histories and physiological systems.  
Foremost is time; flies live for just 10 weeks and is not possible to study all the impacts of 
longevity on the disease process. Whilst some aspects of longevity such as aging and the 
progressive nature of tau phenotypes can be studied in flies, for other aspects of disease 
that seem to require long periods for maturation (e.g. tau aggregation into large filaments 
and tangles) the life span of the fly may not be sufficient.  Similarly, the more divergent 
elements of fly systems make it more difficult to analyse the broader physiological aspects 
of the disease that involve for example adaptive immunity, inflammatory processes or 
pharmacodynamics. For the latter, the mode of drug action may be studied, or a drug target 
may be identified; however, it is not possible to study drug delivery, metabolism, half-life or 
its removal.  Evidently the use of flies is limited to those elements that can be meaningful in 
such a simple, short-lived system. Key in this regard is an appreciation that fly models of 
tauopathy allow one aspect of tau pathology to be simulated in a simple organism so that 
fundamental questions about how this pathology arises and how it impacts neuronal 
structure and function can be addressed. It is important to realise that the aim of working 
with the fly is not to create Alzheimer’s disease in a model, but to emulate molecular 
elements of the disease in order to understand the mechanisms that contribute to the 
neuronal dysfunction and neurodegeneration that gives rise to the clinical symptoms in that 
complex human condition. 
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1.2 The genetic tools that allow modelling of disease in Drosophila 
All models of neurodegenerative disease in Drosophila rely on the GAL4-UAS binary 
expression system that allows for temporal and spatial control of gene expression (Brand 
and Perrimon 1993). The GAL4 system comprises two parts: the GAL4 “driver” line, in 
which an enhancer element drives expression of the yeast transcriptional activator, GAL4, 
in a reproducible temporal and spatial pattern, and the UAS “responder” line, in which the 
sequence of a gene of interest is inserted downstream of the GAL4 Upstream Activation 
Sequence (UAS). Crossing driver and responder lines to combine both elements in the 
same fly results in GAL4 binding to the UAS sequence and initiating expression of a gene 
of interest in a pattern dictated by the driver line. Traditionally these two elements have 
been randomly inserted into the fly genome using p-element mediated transposition (Brand 
and Perrimon 1993); however, site-directed methods using flippases and CRISPR-Cas9 
based genome editing allow insertion of transgenes into specific genomic locations (Bischof 
et al. 2007, Jinek et al. 2012). These latter developments are useful for controlling 
expression level differences between constructs that may arise from random insertion 
methods, making comparative studies of different constructs more consistent.  
 
1.2.1 GAL4-responder lines to express tau and other effectors:   
The key to fly work is that “engineering” a fly to create a transgenic stock 
incorporating a novel UAS responder construct is relatively easy, inexpensive and often 
commercially outsourced, meaning that it is theoretically possible to target the expression of 
any disease related human protein in flies. However, a wealth of extant genetic tools is 
readily available in the fly community and stock centres such as the Bloomington 
Drosophila Stock Centre (BDSC, http://flystocks.bio.indiana.edu). For example, there are a 
number of fly models of tauopathy available that allow expression of different variants of 
htau in the fly’s nervous system and offer well-established, quantifiably assays for detecting 
causal effects. This includes, but is not limited to, GAL4 lines for expressing Drosophila tau 
(dtau) (Mershin et al. 2004), bovine tau (Ito et al. 1997), any of the six wildtype isoforms of 
human tau (Williams et al. 2000, Wittmann et al. 2001, Chatterjee et al. 2009), mutations at 
tau phosphorylation sites specific for particular kinases (Chatterjee et al. 2009, Nishimura et 
al.  2004), mutations that mimic constitutively dephosphorylated or pseudophosphorylated 
states of tau (Khurana et al. 2006) and mutations associated with other tauopathies (e.g. 
R406W tau which is a mutation associated with frontotemporal lobe dementia (FTD) 
(Wittmann et al. 2001). These models have undoubtedly made enormous contributions to 
our understanding of tauopathies, but one could argue that like similar rodent models, there 
are two inherent traits that should be borne in mind when interpreting results: all these 
models invariably express the htau in flies already expressing endogenous dtau, and the 
htau gene may potentially be “over-expressed” because there is little information about how 
the htau expression compares to that of the endogenous dtau. How htau impacts 
endogenous dtau, and whether or not this contributes to the htau phenotype is not always 
clear, though some studies have examined this (Cowan et al. 2010a). Such issues affected 
rodent models of tauopathy for decades and have led to newer rodent models wherein the 
htau is expressed in transgenics in which the rodent tau has been removed.  This approach 
is also being adopted by Drosophila biologists, who are beginning to create similar 
“humanised” fly models – in these newer fly models, dtau is deleted and the htau gene is 
“knocked-in” into the dtau locus (Gorsky et al. 2017). Expression of htau is then controlled 
by endogenous dtau regulatory elements. It is conceivable that these newer models may 
enable an even closer emulation of disease because they will achieve physiological htau 
expression without any confounding influence (if any) of endogenous dtau.  
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Stock centres such as the BDSC also offer thousands of useful UAS responder lines 
that allow fluorescent labelling of entire cells, subcellular compartments (e.g. nucleus, 
cytoplasm, dendrites, synapses, etc.) and subcellular components (e.g. organelles such as 
mitochondria, labelling of endosomes, lysosomes etc.). These reagents are useful for 
assaying cell structure and essential cellular processes and have been employed by fly 
biologists to understand how tau variants affect neuronal structure and function.  Most 
commonly UAS-mCD8-GFP has been used to label neuronal membranes to study the 
impact of tau on overall neuronal structure (Williams et al. 2000). To examine the role of tau 
on different neurobiological processes, responder lines such as UAS-mito-GFP (Pilling et 
al. 2006) have been used for examining cellular distribution and trafficking of mitochondria 
in neurons (DuBoff et al. 2012), GFP tagged neuropeptide Y (UAS-PU32M2) has been 
used for examining axonal transport defects in motor neurons (Mudher et al. 2004), UAS-
syt-GFP (Robinson et al. 2002) has been used for visualizing synaptic vesicles and 
terminals (Talmat-Amar et al. 2011), and UAS-LifeAct (Riedl et al. 2008) has been used for 
labelling F-actin (Frost et al. 2016). In addition to these responder lines there are many 
other transgenic lines for probing neuronal structure and function (reviewed in 
Sivanantharajah and Zhang 2015) that have yet to be fully employed in the tauopathy field 
but may prove to be useful for answering particular questions, especially in the face of 
newer roles that are now emerging for tau (reviewed in Sotiropoulos et al. 2017). Some 
examples for labelling cell substructure include: UAS-DenMark for dendritic processes 
(Nicolaï et al. 2010) and UAS-EB1-GFP for labelling microtubule plus-ends (Rolls et al. 
2007). In addition, it is possible to label organelles such as recycling endosomes (UAS-
Rab4-RFP) (Sweeney et al. 2006, Zheng et al. 2008), active zones (UAS-BRP-GFP/RFP) 
(Fouquet et al. 2009), post-synaptic density (UAS-Dlg-GFP) (Koh et al. 1999) or even 
specific types of neurotransmitter receptors (e.g. UAS-GluRIIA-GFP/RFP for ionotropic 
glutamate receptors) (Jordán-Álvarez et al. 2012).  The availability of these genetic tools 
and the ease of their use sets the fly apart as one of the most powerful systems for 
dissecting cellular level processes involved in disease pathogenesis and progression.     
 
Of importance for both identifying and verifying genetic modifiers employable in 
large-scale enhancer/suppressor genetic screens, for which the fly is particularly suited, 
there are large collections of responder lines that allow targeted downregulation of specific 
genes. The available RNAi libraries cover 90% of the fly genome and allow targeted 
knockdown of specific genes using the GAL4-UAS system (Dietzl et al. 2007, Ni et al. 
2008). UAS-dsRNAi lines are often co-expressed with UAS-tau expressing constructs to 
knock down genes of interest to study their ability to modify tau mediated phenotypes. 
Often these vast RNAi libraries are used to screen for tau modifiers, genes that enhance or 
suppress tau toxicity (Butzlaff et al. 2015).  RNAi lines can also be used to validate putative 
tau modifiers identified by other methods such as microarray analyses or Genome-wide 
association studies (GWAS) (Dourlen et al. 2017, Shulman et al. 2011, Karsten et al. 2006). 
 
Fortunately for the study of tauopathies in flies, there is a fly orthologue of tau; 
however, this is not the case for all human disease-associated genes for which GAL4 
responder lines exist. For example, there is no homologous protein for alpha-synuclein 
which is implicated in Parkinson’s disease.  The case of Amyloid- (A) peptide, which 
constitutes the plaque pathology in AD, is more complicated. Though an orthologous parent 
protein, β amyloid protein precursor-like (APPL), is present in the fly, the A peptides 
produced by cleavage bare no sequence similarity to human A peptides; however, the 
ability of fly A-like peptides to aggregate and cause age-dependent dysfunction and 
degenerative phenotypes suggests it may be secondary structure of A peptides rather 
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than primary amino acid sequence that determines pathogenesis (Carmine-Simmen et al. 
2009).  These cases raise interesting questions about the impact of expressing such 
proteins in fly models of amyloidosis or Parkinson’s disease. On the one hand, one may ask 
whether the fly systems will treat these proteins as “alien proteins” when they are artificially 
expressed in fly neurons or will they interact in ways comparable to models in which these 
proteins exist (e.g. as seen with fly A)?  On the other hand, one may view these models as 
ideal platforms for identifying interacting partners without confounding influences of a native 
orthologue.  
 
1.2.2 GAL4-driver lines to control where and when tau is expressed 
Stock centres provide thousands of driver lines that can target gene expression in 
general cell-types (e.g. all neurons, all glia, etc.) to very specific cell-types (e.g. neuronal 
subtypes such as motor or sensory, neurons using a particular neurotransmitter, etc.).  
Added to this, the Janelia FlyLight project has generated thousands of driver lines that allow 
visualization and manipulation of small specific cell-types in the larval and adult nervous 
systems (Pfeiffer et al. 2008, Jenett et al. 2012). This newer set of driver lines will be an 
invaluable tool for those seeking to study the effects of disease-associated proteins at the 
level of different neuronal subsets.  
 
Published studies using fly models of tauopathy have used different strategies to 
express different variants of tau protein (htau isoforms, bovine tau, fly tau, disease-
associated variants of htau, etc.) with vastly differing levels of spatial and temporal 
specificity. These strategies range from global expression models using pan-cellular drivers 
such as elav-GAL4 and Repo-GAL4 to drive expression in all neurons and all glia, 
respectively, in the CNS (Colodner and Feany 2010, Wittmann et al. 2001) through to 
region-based models targeting expression to particular brain structures such as the eye 
(Jackson et al. 2002) or the mushroom bodies (MB) (Mershin et al. 2004) to tau expression 
in specific cell-types such as motor neurons (Chee et al. 2005, Mudher et al. 2004), sensory 
neurons (Sealey et al. 2017, Williams et al. 2000) or neurons using a particular 
neurotransmitter type (Nishimura et al. 2004, Wu et al. 2013, Wittmann et al. 2001).  Table 
1 summarises various fly models of tauopathy organised by tissue-level specificity of study 
(e.g. entire CNS, regional, cell-type specific) and the GAL4 drivers commonly used.  Each 
of these strategies has advantages and disadvantages. Ideally the experimenter knows the 
limitations of each approach and draws conclusions accordingly.  In the next section we 
provide greater detail about the advantages and limitations of the most commonly used 
strategies.   
 
 
2 The most commonly used Drosophila models of tauopathy:  
2.1. Global expression models 
Pan-neuronal expression of tau allows one to understand the central nervous 
system’s response to tau expression. Many studies have driven expression of tau using the 
pan-neuronal driver, elav-GAL4, and quantified the subsequent effects either: histologically, 
on overall brain anatomy or particular brain regions (e.g. MB), biochemically, measuring 
levels and patterns of phosphorylation or protein solubility, or behaviourally, looking for 
deficits in locomotion or learning and memory (Sealey et al. 2017, DuBoff et al. 2012, 
Papanikolopoulou et al. 2010, Kosmidis et al. 2010, Folwell et al. 2010, Fulga et al. 2007, 
Wittmann et al. 2001).  Similarly, the role of glia can be tested by targeting tau expression 
to all glial cells using the driver, Repo-GAL4 (Colodner and Feany 2010), and structural and 
functional effects of tau in glia can be analysed as they are for neurons.  
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Pan-neuronal expression studies of tau-mediated toxicity have played a major role in 
our current understanding of how tau abnormalities arise.  Wittman et al. (2001) were the 
first to use elav-GAL4 to drive expression of human wildtype (0N4R tau isoform) and 
mutant tau proteins (R406W) in the fly CNS. These experiments demonstrated the ability of 
wildtype htau overexpression to cause neurodegeneration and significantly shorten 
lifespan. Histological analysis of the fly brain following tau expression revealed increased 
numbers of vacuoles and degenerating cells compared to control brains, but more 
importantly, the severity of these phenotypes was enhanced by expression of the R406W 
tau mutant. With this model, the authors also implicated a causal role for 
hyperphosphorylation in mediating toxicity by showing that tau phosphorylation increased 
with age in regions of neurodegeneration (i.e. areas near degenerating cells and vacuoles) 
with no increase in overall tau levels.  
 
Using the same approach, the Skoulakis lab (Papanikolopoulou et al. 2010, 
Kosmidis et al. 2010) demonstrated that pan-neuronal expression of the tau isoforms 0N4R 
and 2N4R also caused severe degenerative defects in the MBs with subsequent abolition of 
olfactory learning.  The observed toxicity and dysfunction in the MB were found to be 
dependent on phosphorylation of tau at two new phosphorylation sites, Ser238 and Thr245, 
indicating that site-specific phosphorylation rather than general hyperphosphorylation of tau 
is key. Subsequent work by this group found an added temporal element to tau regulation 
by phosphorylation showing that sequential phosphorylation at specific sites was essential 
for the progression of learning defects and premature mortality (Papanikolopoulou and 
Skoulakis 2015).  
 
  Another highly informative observation made by the Skoulakis lab was the finding 
that tau toxicity and dysfunction are separable (Papanikolopoulou et al. 2010, Kosmidis et 
al. 2010).  Using the TARGET (Temporal and Regional Gene Expression Targeting) 
system, they supressed tau expression during developmental stages to restrict tau 
expression to only post-mitotic adult neurons, since elav is expressed early in neuronal 
development (Berger et al. 2007).  Briefly, the TARGET system introduces a temperature-
sensitive repressor of GAL4, GAL80ts, which is expressed in all cells using a tubulin 
promotor. Shifting incubation of flies between permissive and restrictive temperatures 
allows regulation of GAL4 mediated transcription. At the non-permissive temperature of 
18°C, GAL80ts suppresses GAL4 function and thus suppresses expression of any UAS 
responder construct. At 29-30°C, GAL80ts is deactivated allowing GAL4 mediated 
expression to occur. They found that tau expression during development was required to 
see the morphological degenerative phenotypes in adult MBs with expression of 0N4R and 
2N4R tau isoforms; however, the lack of tau mediated degeneration, did not translate to a 
lack of neuronal dysfunction. Although these 0N4R and 2N4R tau-expressing flies had 
histologically normal MBs, there was still a significant impairment in their performance in 
learning tasks. This is an important observation demonstrating a clear de-coupling of tau 
mediated neurodegeneration and neuronal/behavioural dysfunction. It also demonstrates 
that neuronal dysfunction which precedes neurodegeneration can be significant enough to 
manifest in a behavioural phenotype. Similar conclusions can be drawn from the findings of 
other Drosophila models of tauopathy where tau expression was restricted to other 
neuronal populations (Chee et al. 2005, Mudher et al. 2004). In these studies, htau 
expression led to quantifiable functional defects but in the absence of overt degeneration.  
  
One general observation in all of these studies is that the severity of phenotypes 
produced by tau overexpression is dependent on the specific tau variant examined (i.e. 
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wildtype isoforms and mutant versions).  For example, mutant tau proteins such as R406W 
show a greater level of toxicity compared to wildtype tau.  Even between wildtype tau 
isoforms, however, there can be variation. For example, pan-neuronal expression of 0N3R 
tau did not cause MB degeneration, whereas, expression of 0N4R and 2N4R tau isoforms 
did (Papanikolopoulou et al. 2010); a result mirrored by Malmanche et al. (2017) in the fly 
eye model.  Though 0N3R tau seems to have no effect on neuronal degeneration, Sealey 
et al. (2017) found that expression of 0N3R tau caused a reduction in longevity and a faster 
decline in climbing ability than did 0N4R.  Conversely, when these two isoforms were 
compared for their effect on learning and memory, 0N4R tau caused impairment but 0N3R 
did not.  These examples illustrate differences between tau isoforms which can be useful in 
understanding differing pathology between 3R and 4R tauopathies.  
 
Global expression of tau in glial cells has also been informative in understanding tau-
mediated toxicity.  A glial model of tauopathy was created by expressing 0N4R tau in all 
glial cells (except midline glia) using the Repo-GAL4 driver (Colodner and Feany 2010).  
Unlike pan-neuronal expression, pan-glial expression of tau during development is lethal; 
but using the TARGET system to restrict expression to adult glial cells produced 
phenotypes comparable to pan-neuronal expression, such as reduced lifespan and age-
dependent cell death. Perhaps the most interesting element of this work was to show the 
cell non-autonomous effect of tau expression in glia caused death in non-tau expressing 
neurons, thus illustrating the importance of glial-neuron interactions in disease. 
 
2.1.1 Cellular mechanisms and toxic tau species in pan-cellular models: 
The mechanisms mediating tau toxicity have been intensely studied in multiple 
experimental paradigms. The role of phosphorylation and aggregation in these mechanisms 
is evident from many such studies (Šimić et al. 2016). As described below, Drosophila 
models of tauopathy have made valuable contributions to our understanding of the complex 
role of tau phosphorylation and aggregation in pathogenesis, as well as identifying other 
novel cellular mechanisms of tau toxicity.  
One such mechanism involves the actin cytoskeleton. Expression of R406W tau has 
been shown to cause accumulation of F-actin and the formation of actin-rich rods in 
degenerating neurons (Fulga et al. 2007), indicating an interaction between the actin 
microfilament network and the microtubule cytoskeleton that is dependent on normal tau 
function.  A second cellular mechanism is tau-mediated mitochondrial dysfunction.  DuBoff 
et al. (2012) found that expression of R406W tau caused elongation of mitochondria as well 
as mitochondrial dysfunction and cell death. These phenotypes could be rescued by 
modulating the expression levels of proteins involved in mitochondrial dynamics (i.e. fission 
and fusion) such as dynamin-related GTPase (DRP1) and mitochondrial assembly 
regulatory factor (MARF). Furthermore, expression of E14 tau (a variant of tau that has 
been pseudophosphorylated by Glu substitution of Ser and Thr at 14 proline-directed 
kinase target sites) caused greater elongation of mitochondria suggesting that 
hyperphosphorylation of tau plays a role in the severity of toxicity.  A third mechanism of tau 
toxicity is highlighted by examining the lamin nucleoskeleton, which is a diffuse scaffold 
composed of lamins, intermediate filament proteins, on which genomic DNA is anchored to 
the nuclear envelope. Frost et al. (2016) showed that expression of R406W tau resulted in 
nuclear lamin invagination, tau hyperphosphorylation, activation of the cell cycle, and 
apoptosis.     
Yet another mechanism worth examining is the interaction between tau and other 
disease-associated proteins such as Amyloid- (A42) and alpha-synuclein. It was found 
that co-expression of these proteins enhanced the phenotypes seen when either protein 
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was expressed alone in both locomotor and longevity assays (Folwell et al. 2010, Roy and 
Jackson 2014).  The tau/Ab42 exacerbation phenotypes were rescued following treatment 
with LiCl, an inhibitor of GSK-3/shaggy (sgg), indicating that phosphorylation plays a role 
in the interaction between tau and A.  
 
Pan-cellular expression experiments in fly have also been informative in 
demonstrating the complex relationship between tau toxicity and tangle formation. In their 
first study, Wittman et al. (2001) demonstrated that tau-mediated degeneration following 
pan-neuronal tau expression does not require tau aggregation into tangles. This is also 
supported by other studies that restricted tau expression to specific neurons types, such as 
sensory or motor neurons (Williams et al. 2000, Mudher et al. 2004).  Like Wittman et al. 
(2001), these studies also reported tau-mediated phenotypes in the absence of overt tau 
tangles, further dissociating tau-toxicity and tangle formation.  Adding to this argument, 
Cowan et al. (2015) found that rescue from tau dysfunction resulted in formation of non-
toxic, insoluble tau oligomers. This implies that like tangles, insoluble tau oligomers are also 
not required for tau-mediated dysfunction or degeneration. This leaves the possibility that 
soluble tau oligomers, rather than larger insoluble tau aggregates are the toxic species in 
tauopathies (reviewed in Cowan and Mudher 2013) and should be targeted by disease-
modifying therapeutic interventions. Indeed, some studies have demonstrated appearance 
of oligomeric tau species at various time-points correlating to disease progression (Wu et 
al. 2013, Ali et al. 2012).  In sharp contrast, pan-glial expression of tau does result in the 
formation of fibrillary tangles in glial cells (Colodner and Feany 2010).  This demonstrates 
that it is not necessarily the shorter lifespan of Drosophila that is responsible for the lack of 
tau aggregation in most fly models and that other, possibly tissue dependent factors, play a 
role in this pathological process.  An interesting observation in this study was that switching 
off tau expression in 20-day old flies for 10 days caused a reduction in observed cell death; 
but this reduction in tau-mediated cell death was not correlated with a reduction in total 
tangle number. This serves to further underline the dissociation between tau toxicity and tau 
tangles, at least in Drosophila models of tauopathy.  
 
2.2 Targeting specific brain structures: the eye and mushroom bodies 
2.2.1 Targeting tau to the fly eye 
Greater cellular resolution can be achieved by restricting tau expression to specific 
brain structures, such as the fly eye and mushroom bodies. Using eye-specific GAL4 
drivers, expression of tau in the eye produces a “rough eye” phenotype which is reflective of 
retinal cell degeneration. This is most commonly done using the GMR-GAL4 driver line, but 
rough eyes can also be generated using sev-GAL4 (a more selective eye driver) as well as 
elav-GAL4.  The eye is used as a target because it provides a clearly visible phenotype that 
is easy to define and quantify, thus making it amenable to high throughput 
enhancer/suppressor screens. Such screens have enabled the unbiased identification of 
novel modifiers of disease-associated proteins and pathways involved in disease 
processes.  For example, Butzlaff et al. (2015) screened for modifiers of R406W tau-
induced toxicity by examining more than 7000 RNAi lines which covered more than half of 
all protein coding fly genes and equivalent to over 90% of the fly genes known to have 
human orthologs. The screen identified 62 genes that, when silenced, modified tau-induced 
toxicity.  Standout genes identified were three subunits of the Dynein/Dynactin complex, a 
key part of the axonal cytoskeleton and retrograde axonal transport mechanism (Kardon 
and Vale 2009). The validity of these candidates was tested using larval motor neurons 
showing that pan neural R406W tau expression coupled with the silencing of 
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Dynein/Dynactin complex members had strong pathological effects in the axon, inhibiting 
retrograde but not anterograde axonal transport with only minor changes at synapses. This 
work suggests that an early step in the pathogenic process is axon degeneration.  
Ambegaokar and Jackson (2011) used the eye for a functional genetic screen using 
loss-of-function and gain-of-function alleles to identify modifiers of tau-induced neurotoxicity 
using the 2N4R tau isoform.  This study identified a wide range of modifiers that included 
some well-known tau kinases including GSK-3/sgg, PAR-1/MARK, CamKI and Mekk1. A 
large proportion of the identified genes included genes involved in diverse cellular functions 
such as: autophagy, cell-cycle, RNA-associated proteins and chromatin-binding proteins. 
Smaller numbers of identified genes included mitochondrial proteins, lipid trafficking, golgi 
proteins, kinesins and dynein and the Hsp70/Hsp90-organizing protein (Hop). The work 
opened the way for complex network analysis to identify regulatory networks and suggested 
several other genes highly associated with these functional modifiers, including genes 
related to the PI3K, Notch, BMP/ TGF-b and Hedgehog pathways, and nuclear trafficking. 
This study serves to illustrate the power of the eye as a platform for such large-scale 
screens and the ability to open up completely new avenues of investigation.  
In the context of the outcomes of a screen, the fly eye also provides a platform for 
more directed approaches to study novel putative tau phenotype modifiers, be they 
identified through such enhancer/suppressor screens as above, or from microarray 
analyses or human GWAS studies (Karsten et al. 2006, Dourlen et al. 2017, Shulman et al. 
2011).  The approach is exemplified by the work of Dourlen et al. (2017) who took 19 loci 
identified in a GWAS meta-analysis for AD and used Drosophila to screen constructs 
targeting orthologs of candidate risk genes within these loci for their ability to modify tau 
neurotoxicity. They identified several tau toxicity modulators including: Drosophila Amph 
(ortholog of BIN1), p130CAS (CASS4), Eph (EPHA1), Fak (PTK2B) and Rab3-GEF 
(MADD). Using the fly eye to validate the outcomes of such screens is still in its infancy but 
it is clear that the fly will become an important tool in the validation of putative interacting 
genes.  Furthermore, the high throughput nature of this type of screening could also lend 
itself to large scale drug screening.  In this light, the fly provides the perfect organism to do 
“proof-of-principle” studies, because one can test hypotheses in large scale and in a short 
span of time before attempting targeted smaller-scale similar studies in models that are 
more expensive and laborious to use. 
 
Beyond genetic screens, the fly eye has also been informative for dissociating tau 
mediated toxicity and dysfunction and the role of tau phosphorylation in each. Chouhan et 
al. (2016) found that expression of htau using Rh1-GAL4, a driver that is turned on after 
photoreceptor maturation, resulted in no degeneration of the fly retina; in fact, experimental 
and control retinas were indistinguishable.  However, ultrastructural analysis found some 
disruption of photoreceptors and synaptic organization and a functional analysis of the 
retina using electroretinograms (ERG) showed that htau expressing flies had a significant 
loss in ERG responses, most likely due to photoreceptor dysfunction. This observation is 
further informed by the work of Malmanche et al. (2017) who showed that developmental 
effects of tau were isoform specific. Where the 4R taus (2N4R and 0N4R) induced a rough 
eye phenotype when driven by GMR-GAL4, 0N3R did not. Together, these studies 
demonstrate an important division between tau-mediated degeneration versus dysfunction.  
 
2.2.2 Cellular mechanisms for tau toxicity and dysfunction in the eye model 
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The fly eye is not just of value in wide-scale screens and functional testing it has also 
contributed enormously as an experimental platform to dissect cellular mechanisms of tau 
induced degeneration.  One well-studied mechanism is phosphorylation of tau and the role 
of putative tau kinases and impact of differential site-specific phosphorylation.  Abnormal 
tau hyperphosphorylation has traditionally been implicated in mediating tau-loss-of-
microtubule binding function effects (Iqbal et al. 2008, Grundke-Iqbal et al. 1986), and as 
described here and in later sections of this review, studies in Drosophila have provided 
further support for this hypothesis (Quarishe et al. 2013, Cowan et al. 2010b, Quraishe et 
al. 2017).  Additionally, evidence from Drosophila models has also shed light on the role of 
tau phosphorylation in neurodegeneration and its potentially complicated role in influencing 
tau aggregation. That hyperphosphorylation accompanies neuronal dysfunction and 
neurodegeneration has been demonstrated by many groups (Wittmann et al. 2001, Mudher 
et al. 2004, Sealey et al. 2017 and others). However, the causal role of site-specific 
phosphorylation in differentially contributing to neuronal dysfunction (via reduced 
microtubule binding) and neurodegeneration has come from Drosophila models employing 
phospho-mimicking or non-phosphorylatable tau mutants expressed in the fly eye.  
 
Pioneering these studies, Nishimura et al. (2004) showed that the Drosophila PAR-1 
kinase can initiate tau toxicity by triggering a temporally ordered phosphorylation of tau, 
directly phosphorylating tau at Ser262 and Ser356. This phosphorylation event is a 
prerequisite for the activity of downstream kinases, such as GSK-3/sgg and Cdk5, to 
phosphorylate other sites and generate disease-associated phospho-epitopes. This was a 
powerful study that began to dissect the effects of phosphorylation on tau toxicity and 
opened the door to new potential routes to therapeutic targets. Following on from this, the 
work of Chatterjee et al. (2009) found that resistance of tau to phosphorylation by GSK-
3/sgg caused substantially greater toxicity due to greater affinity for microtubule binding 
than wildtype tau. Together these studies suggest that tau phosphorylation at the PAR-
1/MARK sites (e.g. Ser262 and Ser356) cause neurodegeneration while tau phosphorylated at 
the GSK-3/sgg (e.g. Ser202, Thr205, Thr212, Ser214, Thr231, Ser396, Ser404) cause dysfunction, 
possibly via microtubule binding effects.  
 
A second mechanism of toxicity that has emerged from studies conducted in the fly 
eye is autophagy, an important element of normal cell physiology that is implicated in a 
number of neurogenerative disorders.  Bakhoum et al. (2014) used the fly eye to show that 
autophagy could play a role in tauopathies. They found that misexpression of htau induced 
accumulation of autophagic intermediates with large vacuoles, termed giant autophagic 
bodies (GABs), which are indicative of autophagic dysfunction. Furthermore, inducing 
autophagy could rescue the tauopathy phenotype, suggesting that formation of GABs may 
be a compensatory mechanism rather than a trigger of neurodegeneration and that 
disruption of autophagic processes may play a key role in the progression of tau pathology.  
 
A third mechanism is protein glycosylation, which has been reported to be altered in 
AD brains (Butterfield and Owen 2011, Kanninen et al. 2004, Schedin-Weiss et al. 2014, 
Zhu et al. 2014). The role that protein glycosylation plays in AD pathology is largely 
unknown. To begin to unravel glycosylation as a possible mechanism of the degenerative 
process, Frenkel-Pinter et al. (2017) used tau overexpression in the fly eye as the basis to 
analyse the effects of reducing the expression of fly homologs of glycosylation-related 
genes identified from a bioinformatics analysis of human studies. They identified 
glycosylation genes that can either augment or ameliorate the tauopathy phenotypes 
suggesting that Ost<Delta>, l(2)not and -4GalT7 are suppressors of tau-mediated toxicity 
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and pgnat5 and CG33303 are enhancers. These novel results suggest that specific 
alterations in protein glycosylation may play a causal role in the progression of AD, and 
present potential therapeutic targets for treatment of disease.   
 
2.2.3 Targeting tau to mushroom bodies 
The mushroom body is the conserved brain centre for learning and memory in 
insects, and as such, can be argued as functionally analogous to the human hippocampus. 
Structurally it is made up of glia and three major classes of neurons (Lee et al. 1999). 
Manipulating tau expression in mushroom bodies has been essential in demonstrating a 
conserved role of tau in learning and memory in flies. Assessing the impact of tau on 
mushroom bodies has been done in two ways: by examining their structure and function 
upon expression of tau using pan-neuronal drivers such as elav-GAL4 (see section 2.1) or 
late onset drivers such as c492 and c772. Restriction of tau expression to post-mitotic 
neurons in the mushroom bodies has been key in detangling tau-mediated toxicity from tau-
mediated dysfunction. The results of using the TARGET system to limit elav-GAL4 driven 
tau expression to adult mushroom bodies are discussed above. When driven by elav-GAL4, 
tau has an effect on mushroom body structure and function; however, every neuron in the 
central nervous system has also been exposed to insult by tau expression so one needs to 
appreciate that the behavioural output from such studies may reflect the collective impact of 
tau on a number of circuits.  Use of post-mitotic drivers that are spatially restricted to MBs 
provide greater cellular resolution and have revealed similar results. Mershin et al. (2004) 
saw an effect on associative olfactory learning and memory upon expression of tau proteins 
in MB neurons, but olfactory conditioning-relevant osmotactic and mechanosensory 
responses were not affected. These behavioural phenotypes were observed without overt 
neurodegeneration of MB neurons or any effect on longevity.  These studies once again 
stress that tau-mediated dysfunction can manifest in behavioural phenotypes prior to onset 
of neurodegeneration or in fact tangle formation. 
 
2.3 Targeting selective subtypes of neurons: motor, sensory, neurotransmitters  
Targeting expression of tau to single or small numbers of neurons provides a tool to 
begin to understand the mechanisms of tau mediated toxicity and dysfunction at single cell 
resolution and gain insights into the cellular mechanism that underlie these processes. 
Typically, this approach has targeted expression of tau to specific neuronal subtypes such 
as sensory and motor neurons or neurons that use a particular neurotransmitter.  In the first 
study examining the impact of htau in a fly model, Williams et al. (2000) expressed tau 
using c161-GAL4, which targets expression specifically to proprioceptive sensory neurons, 
and uncovered several indicators of neurodegeneration: axon loss, axon defasciculation, 
reduced arborization and axonal swellings. The work also reported that phenotypic severity 
increased with age, as would be expected of an age-dependent neurodegenerative 
process.  Sensory neurons have also been used to understand isoform specific differences. 
Sealey et al. (2017) compared toxicity of 0N3R and 0N4R taus in sensory neurons in the fly 
eye using R7-GAL4 and found greater degeneration of neurons with 0N4R at 20 days than 
with 0N3R tau. This work demonstrated a key difference in the behaviour of two wildtype 
tau isoforms in that 0N4R tau causes greater overall toxicity to neurons than 0N3R tau. 
 
A more commonly used approach in the field is to drive expression in larval motor 
neurons, using drivers such as D42-GAL4 and OK6-GAL4, and visualize activity within 
readily accessible larval motor neuron axons and the neuromuscular junction (NMJ) using 
assays for axonal transport and synaptic function, respectively. The larval NMJ is a widely 
used system to analyse the mechanisms of synapse formation, growth and maintenance 
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(Menon et al. 2013, Keshishian et al. 1996).  This model affords numerous advantages in 
that it allows analysis of the effects of tau expression with subcellular resolution, meaning 
that one can quantify effects on clearly visible individual synaptic boutons (Chee et al. 
2005) and examine axon transport defects along well-defined peripheral nerves in real time 
and in living intact animals (Mudher et al. 2004). Most importantly, this system is amenable 
to electrophysiology, which allows direct measurement of neuronal function (Chee et al. 
2005). Using this model, it was shown that some of the earliest consequences of tau 
expression is breakdown of the axonal cytoskeleton and the disruption of axon transport 
leading to the aggregation of transport vesicles (Mudher et al. 2004). As a result of these 
transport defects there is a lack of functional mitochondria at the NMJ causing synaptic 
dysfunction and compromised synaptic vesicle cycling causing a diminution of synaptic 
transmission (Chee et al. 2005).  This system has also been useful in demonstrating 
isoform dependent differences in tau-mediated dysfunction. Sealey et al. (2017) found that 
0N3R tau but not 0N4R tau caused locomotor dysfunction and impaired axon transport, 
again demonstrating an association of 4R isoforms are with greater toxicity and 3R isoforms 
with greater dysfunction. 
 
Using the same system as background and using both axon transport and locomotor 
phenotypes caused by tau expression, Mudher et al. (2004) demonstrated that expressed 
htau is abnormally phosphorylated. Co-expression of an activated GSK-3  exacerbated the 
tau phenotypes and conversely, inactivation of GSK-3 by lithium chloride (a GSK-3 
inhibitor) reversed them. This suggested that the tau induced phenotypes are regulated by 
tau phosphorylation.  Subsequent work with this model showed that the mechanism by 
which htau mediates its toxic effects is twofold: first, highly phosphorylated tau has 
reduced binding to microtubules, and second, it sequesters dtau from microtubules, 
implicating both a toxic-loss-of function and toxic-gain-of function in the context of 
microtubule binding. A consequence of this is disruption of the microtubular cytoskeleton, 
resulting in a reduction in the number of intact, correctly-aligned microtubules and 
incorrectly oriented microtubules. These effects were phosphorylation dependent ass 
suppression of tau phosphorylation increased microtubule binding of both htau and dtau 
and restored cytoskeletal integrity (Cowan et al. 2010b).  These results are further 
supported by Talmat-Amar et al. (2011), who found that AP tau (a variant of tau that has 
been hypophosphorylated by Ala substitution of Ser and Thr at 14 proline-directed kinase 
target sites) had a greater affinity for microtubules than htau or E14 tau and caused 
significant axon transport defects when expressed in larval motor neurons. Together with 
studies from the eye model, it is clear that excessive (as described by Chatterjee et al. 
2009, Talmat-Amar et al. 2011) and sub-optimal (as described by Mudher et al. 2004, 
Cowan et al. 2010b) microtubule binding is detrimental.  
 
In addition to the influence of phosphorylation on microtubule binding, some 
theories propose that it stimulates tau aggregation and therefore may have a two-fold 
mechanism of toxicity. However, in the studies of Mudher et al. (2004) and Cowan et al. 
(2010b) there was no evidence of hyperphosphorylation causing tau aggregation. This 
demonstrates that hyperphosphorylation induced loss-of-microtubule binding function is 
sufficient to cause neuronal dysfunction and behavioural deficits, and these phenotypes 
are independent of tau aggregation. Subsequent studies demonstrated that microtubule 
stabilising agents rescued these phenotypes and intriguingly did so without reducing tau 
phosphorylation (Quraishe et al. 2016). This highlights the critical role played by loss of 
tau’s microtubule-binding function in mediating neuronal dysfunction in early (pre-tau 
aggregation) stages of disease.  
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Other experiments have chosen to focus on the effect of targeting tau to neuron 
subtypes on the basis of their primary neurotransmitter system, with a focus on the 
cholinergic system which is implicated in AD (Sims et al. 1983). Wittman et al. (2001) used 
Cha-GAL4 to examine the effect of htau on cholinergic neurons in the central complex of 
adult flies and found evidence of neurodegeneration without any subsequent effect on 
longevity.  Nishimura et al. (2004) used the same driver to show a greater amount of 
phosphorylation at two sites, S262 and S356, in the microtubule binding domain of htau in 
cholinergic nerve terminals in the optic medulla when PAR1 kinase and htau were co-
expressed; levels higher than when either were expressed alone. They also noted 
neurodegeneration (e.g. vacuole formation) in cell bodies and processes in the giant 
interneuron commissure with co-expression of PAR1 and h-tau. These effects of tau are 
likely to result from the presence or absence of molecular factors such as tau kinases or tau 
phosphatases in these neurons rather than a preferential susceptibility of cholinergic 
neurons to tau-toxicity.  
 
Expanding on tissue-specific susceptibility, Wu et al. (2013) compared the effect of 
tau expression on a wider range of neurotransmitter-specific cell-types, including dopamine, 
GABA, serotonin and glutamate. They showed that expression of tau in dopaminergic, 
serotonergic and some peptidergic neurons produces a marked decrease in the number of 
those neuron types in the adult brain. In contrast, expression of tau in glutamatergic and 
GABAergic neurons did not produce any loss of neurons. Importantly, this was one of few 
studies to have demonstrated bona-fide tau aggregates in Drosophila CNS neurons. Tau 
oligomers, filaments and tangle-like structures were demonstrated when tau was expressed 
in dopaminergic neurons using a number of techniques (biochemical, ultrastructural and 
immunohistochemical).  Here too, one may argue the susceptibility of the neuronal 
populations that succumbed to tau-mediated degeneration may arise due to factors 
promoting tau phosphorylation and aggregation. Further studies are needed to compare the 
tau kinase/phosphatase profiles of susceptible and resistant cell-types, as well as their 
endogenous protein clearance capabilities to understand how they confer vulnerability or 
resistance to tau-mediated degeneration. This is one area of research that can benefit 
enormously from the superior genetic tractability of Drosophila, that can enable such 
studies more easily than in other models of tauopathy. 
 
 
3 Considerations for commonly used Drosophila models of tauopathy 
3.1 Controlling for expression levels of responder lines in comparative studies: 
As with studies on all animal systems, many of the foundational tools used to study 
neurodegeneration in Drosophila have some limitations in the spatial and temporal aspects 
of disease-gene expression. However, the field is constantly evolving and developing new 
genetic tools and knowledge that allow us to undertake more precisely defined 
experiments. For example, gaining better control of expression levels of tau transgenes 
across studies to help comparative studies of tau isoforms, tau mutants, or different 
disease-causing proteins. It is arguable that though this limitation of disease-gene 
expression affects all model systems, the genetic tractability of flies makes them the most 
amenable to overcoming such limitations than any other model system.  The first-
generation responder lines were typically inserted randomly into the fly genome and 
expression levels of different proteins were not always same as the result of genomic 
position effects on transcriptional levels, even when using the same GAL4 driver. To bring 
better consistency to comparative experiments and reduce expression level differences, 
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tools have been developed that can minimise these differences. For example, using fly lines 
in which transgenes are inserted into the same genomic location to reduce site-dependent 
effects on expression levels as done by Fernius et al. (2017), who showed that when 
inserted in same genomic location expression of all six hTau isoforms exhibited comparable 
toxicity in flies.  Alternatively, it is possible to use a more natural expression system by 
replacing the endogenous dtau coding region with the htau coding sequence (Gorsky et al. 
2017).  This has a two-fold impact by eliminating endogenous tau expression, and by 
driving htau expression at normal physiological levels. Using this approach Gorsky et al. 
(2017) found that although naturally expressed htau had no effects on the morphology or 
physiology of expressing neurons, it did ameliorate an Amyloid- phenotype and acetylation 
at specific tau residues supressed phosphorylation and microtubule binding. The 
importance of this lies in the ability to distinguish between tau functions and modifications 
evident under normal physiological conditions from scenarios when it is overexpressed.   
 
3.2 Developmental expression of tau 
One concern with some commonly used Drosophila tauopathy models is that the 
ensuing phenotypes could be developmental in nature. Pan-neural drivers such as elav-
GAL4 are expressed during early neural development, including in neuronal precursor cells.   
Similarly, some eye-specific drivers such as GMR-GAL4 and sev-GAL4 are expressed 
during development in cells of the differentiating eye discs, and in the case of GMR-Gal4 in 
non-neuronal cells such as glia (Freeman 1996, Tomlinson et al. 1987). There is evidence 
that developmental expression of tau can have detrimental effects since driving a tau-lacZ 
transgene in rapidly dividing cells using an engrailed-GAL4 driver interferes with mitosis 
and can cause lethality (Phelps and Brand 1998). This implies that one must interpret the 
tau phenotypes obtained using drivers that may drive tau expression developmentally with 
care.  It is important in those models to ascertain whether the neurodegeneration and 
consequent phenotypes reported reflect an age-related pathogenic process (i.e. truly 
modelling age-related disease pathogenesis) or arise due to developmental effects of tau 
expression.  
 
This concern has been addressed by most groups in two ways. First, by selecting to 
study tau phenotypes that are adult onset in nature, where there is no tau phenotype on 
emergence as an adult and that which develops with increasing age (e.g. Sealey et al. 
2017).  Or second, by restricting transgene expression to post-mitotic adult neurons (e.g. 
Papanikolopoulou et al. 2010, Kosmidis et al. 2010, Chouhan et al. 2016 and others). 
Temporal restriction of tau expression can be achieved by using post-mitotic neuronal 
drivers such as APPL-GAL4 for pan-neuronal expression, Rh1-GAL4 in photoreceptors and 
c492-GAL4 and c7772-GAL4 in mushroom bodies.  Alternatively, one could determine the 
expression pattern of the lines of choice in developmental stages before embarking on 
studies with a novel GAL4 line.  If suitable GAL4 drivers cannot be found, tools exist to 
experimentally restrict expression to post-mitotic neurons using inducible systems such as 
TARGET or GeneSwitch (Osterwalder et al. 2001, McGuire et al. 2004), both of which 
provide an experimentally controlled temporal switch for expression. 
 
3.3 Cellular resolution and the heterogeneity of tau processing 
One facet of fly models shared by all disease models including rodents is a lack of 
cellular resolution, especially when using pan-neural GAL4 drivers to drive tau expression. 
This can serve both as a limitation and a strength. It can be a limitation if one wanted to 
understand what underpins region-specific neuronal vulnerability to explain regional 
selectivity in different tauopathies. Alternatively, it may be regarded as a strength if one 
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were to view some tauopathies, like AD, as “systems” diseases, where neuronal 
connectivity underpins spatio-temporal regional spread of disease. Global expression 
experiments give a valuable general impression of how the nervous system collectively 
responds to an insult by toxic protein expression. However, they cannot give nuanced 
information about cell-specific vulnerability of thousands of different neuronal cell-types in 
the brain.  
 
Better spatial resolution of targeted tau expression has been achieved in Drosophila 
studies using brain-region specific drivers (e.g. mushroom body drivers, retinal drivers, 
motor neuron drivers, etc.). By targeting the eye and mushroom bodies, there is improved 
resolution in that tau is targeted to specific brain regions; however, one must also consider 
whether expression in non-neuronal tissues such as glia contributes to the phenotype with 
those drivers. In the case of mushroom bodies, which are a heterogeneous cellular 
structure in which different neuronal subtypes are targeted together, one assumes here that 
all these neuron subtypes respond equally to tau expression.  Larval motor neurons, on the 
other hand may provide single cell resolution and in vivo imaging capabilities but are limited 
in not enabling assessment of age-dependent phenotypes. However, this can be overcome 
by using assays employed in other arenas of Drosophila neurobiology which use adult 
specific drivers with enhanced in vivo imaging capabilities (e.g. wing and leg assays) 
(Vagnoni and Bullock 2016).   
 
Another important consideration is that one cannot always extrapolate results obtained 
from one specific population of neurons to generalise for the entire brain.  Some studies in 
Drosophila have shown cell-type specific differences in tau biochemistry. Grammenoudi et 
al. (2006) found that tau proteins showed different phosphorylation patterns and stability 
when expressed in different neuron subtypes, including photoreceptors, mushroom body 
neurons, and motor neurons. This suggests that different neurons handle tau in different 
ways and that extrapolating results from one neuron type to another does not always paint 
the full picture. This is supported by the conspicuous lack of histologically evident tau 
aggregates upon tau expression in all CNS tissues in Drosophila except dopaminergic 
neurons (Wu et al. 2013) or glial cells (Colodner and Feany 2010).  Given the observation 
that different neurodegenerative diseases show clear associations with specific brain 
regions, which in part is due to selective vulnerability of neurons to toxic proteins, it is 
important to target smaller subtypes of neurons, or even single-cells in order to understand 
the details of the degenerative process. The tools to do this already exist for Drosophila.  
Spatial restriction of tau expression can be achieved by exploiting the rapidly expanding 
array of GAL4-driver lines that offer more precisely targeted and well documented 
expression patterns. These lines allow single-cell or cell-type specific resolution by using 
GAL4 driver lines that restrict expression to small groups of neurons. This has become 
possible using intersectional strategies such as the Split-GAL4 system (Luan et al. 2006) to 
generate lines that drive Gal4 expression in small, specific classes of neurons (Jenett et al. 
2012, Pfeiffer et al. 2010). These lines have yet to be fully applied to the study of 
neurodegenerative disease in flies but provide excellent potential for understanding specific 
elements of the disease process at single cell resolution. 
 
 
4 Summaries and conclusions: 
4.1 Key contributions to the field by the fly  
Collectively, the work presented in this review provide different perspectives of the 
disease mechanisms with each study providing valuable advances in knowledge.  When 
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the discoveries made across different fly models are consolidated, a common story begins 
to emerge that provides insight into the causes of tau abnormalities, the role of these 
abnormalities in mediating tau-mediated toxicity and/or dysfunction and the nature of 
causative species mediating tau-toxicity.   
   
It is traditionally believed that tau becomes pathogenic in tauopathies because it 
becomes abnormally hyperphosphorylation, misfolded and aggregated. Drosophila models 
of tauopathy have contributed to our understanding of the role of hyperphosphorylation in 
tau toxicity. Though kinases and phosphatases known to cause hyperphosphorylation had 
been identified in other experimental paradigms (reviewed in Dolan and Johnson 2010), the 
Drosophila models of tauopathy have identified a number of novel tau kinases including 
components of the JAK/STAT signalling pathway (Colodner and Feany 2010), and Nuak1, 
an AMP-activated protein kinase (AMPK)-related kinase (Lasagna-Reeves et al. 2016) 
amongst others.  Furthermore, the role of known tau kinases in mediating tau 
phosphorylation and the pathological consequences downstream have been further 
elaborated in Drosophila. For example, GSK-3/sgg phosphorylates tau at the same 
epitopes as in rodents and humans, but studies exploring the impact of this kinase on tau in 
the fly have been important in dissecting the specific tau phosphorylation sites associated 
with dysfunction (e.g. microtubule destabilisation) and those associated with toxicity (e.g. 
degeneration) (Nishimura et al. 2004, Chatterjee et al. 2009). This point stresses the 
importance of integrating work from rodents and flies.  Additionally, fly work on tau 
phosphorylation has demonstrated that tau phosphorylation in vivo is multi-faceted – it can 
occur in a sequential manner dictated by previous phosphorylation events (Chatterjee et al. 
2009) and the pattern of phosphorylation is tissue and age dependent (Grammenoudi et al. 
2006, Papanikolopoulou and Skoulakis 2015). How tau phosphorylation influences 
aggregation is not entirely clear, though all Drosophila data imply that the relationship is not 
straight-forward, because while hyperphosphorylation is evident in all models, aggregation 
is not. Indeed, in one model aggregation into tau oligomers was associated with rescue of 
neuronal dysfunction (Cowan et al. 2015). 
 
The genetic tractability of Drosophila lends itself to unbiased enhancer/suppressor 
screens, which have revealed a number of novel cellular mechanisms that may prove 
useful in understanding the wider disease process. This includes, but is not limited to, tau 
phosphorylation by newly characterized kinases such as Nuak1 (Lasagna-Reeves et al. 
2016), the importance of the axonal cytoskeleton and retrograde axonal transport (Butzlaff 
et al. 2015), and the role of autophagy, RNA processing, protein translation and ribosomal-
associated genes (Ambegaokar and Jackson 2011).  Many potential mechanisms have also 
been identified from hypothesis-driven studies which have implicated the actin cytoskeleton, 
the lamin nucleoskeleton, mitochondrial dysfunction, axon trafficking, and synaptic 
dysfunction in tau toxicity. Understanding the root cause of tau toxicity on these cellular 
processes may present focus areas for targeted drug development in disease-modifying 
therapies.  Similarly, the genetic tractability of the fly model enables it to serve as a platform 
to study the role of targets identified from human GWAS studies. This will allow the 
dissection of newly identified disease mechanisms on a larger scale; arguably, this cannot 
be done, at this level, in any other model organism.  
 
Another contribution is the appreciation that tau mediated dysfunction and/toxicity is 
tissue and isoform dependent.  Drosophila models illustrate that the impact of pathological 
tau depends heavily on how a particular tau isoform is handled by a tissue. Some tissues 
are resistant to neurodegeneration whilst others are vulnerable; some phosphorylation 
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profiles, aggregation propensities and even dysfunction versus degeneration phenotypes 
are evident when certain tau isoforms are expressed but not others (Sealey et al. 2017, 
Papanikolopoulou et al. 2010, Kosmidis et al. 2010).  Clearly a “one-size-fits-all” scenario 
does not explain how the six tau isoforms cause dysfunction and degeneration in 
tauopathies. This conclusion can be drawn largely because of what we have learnt from fly 
models of tauopathy, and it is reassuring that rodent models support this idea (McMillan et 
al. 2008). 
 
Lastly, the fly model has been important for illustrating that tau-mediated 
neurodegeneration and dysfunction can occur without the formation of neurofibrillary 
tangles.  This suggests that aggregation and tangle formation during AD is likely to be a late 
or end stage process or one that is specific to cell-type.  It is possible that if flies lived 
longer, they may accumulate toxic tangles, though this seems unlikely because complete 
degeneration of neurons is often seen without tangle formation. However, there are some 
cells in which tangles are observed: glial cells and dopaminergic neurons. Therefore, a 
more likely solution is that cells resistant to tangle formation lack some molecular 
component that facilitates or promotes tau aggregation; whereas, the cellular environment 
of cells like glial cells and dopaminergic cells may be more conducive to tau aggregation 
because such molecular components are more abundant.  Regardless, induction of tau-
mediated toxicity and dysfunction without tangles suggests that the toxic species of 
relevance is really another form of tau, likely soluble, hyperphosphorylation tau. That this 
toxic tau species may be a small soluble aggregate is suggested by a very interesting 
observation by Passarella et al. (2018) who reported a conspicuous absence of tau-
mediated degeneration and behavioural phenotypes in transgenic flies expressing a non-
aggregate prone htau mutant. This hypothesis is not without some corroboration in 
mammals with studies in mice that have shown that tau-mediated dysfunction occurs in the 
absence of neurofibrillary tangle formation and cell death (Kimura et al. 2007), and that 
targeting tau oligomers reverses tauopathy phenotypes in a rodent model of tauopathy 
(Castillo-Carranza et al. 2014).  
  
4.2 Conclusions 
The last two decades has established the fly as a useful animal model to gain rich 
new insights into human neurodegenerative diseases. The tools for use on Drosophila are 
constantly advancing and improving our ability to study human diseases in the fly with 
greater resolution. The combination of precisely controlled disease related transgene 
expression with new reporter lines that allow us to analyse the different functional 
compartments and components of neurons (e.g. cytoskeleton, axon transport, synaptic 
function and organelles, etc.) provides an unparalleled array of tools that can be deployed 
to analyse neurodegenerative processes in the fly. With this will come greater experimental 
insights into disease processes, making the fly the most powerful, non-mammalian in vivo 
system for studying the mechanisms of neurodegeneration.  
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Table 1. Summary of commonly used Drosophila models of tauopathy 
Tissue level 












(i) Observe tau-mediated toxicity 
(e.g.neurodegeneration, shortened 
lifespan) and dysfunction (e.g. climbing 
defects) (Wittmann et al. 2001)  
 
(i) Expression during early neuronal 
development; noted degeneration due to 
developmental tau expression 
(ii) Expression in non-neuronal cells (e.g. 
embryonic glia and glioblasts (Berger et al. 
2007)) 






(i) Can recapitulate disease related 
phenotypes such as tangle formation 
(Colodner and Feany 2010) 
(ii) Can study cell non-autonomous effect 
of glial tau on neurons 
 
(i) Not specific to glial cell-type (expression in all 
glial types except mid-line glia) 
REGIONAL  















(i) Well established assays, easy visual 
phenotype to qualify and quantify 
(ii) Highly amenable to large scale 
modifier/suppressor screens to identify 
tau modifiers (Butzlaff et al. 2015, 
Ambegaokar and Jackson 2011, Dourlen 
et al. 2017, Shulman et al. 2011). 
(iii) Observe tau-mediated toxicity (e.g. 
neurodegeneration) and dysfunction (e.g. 
reduction in retinal function (Chouhan et 
al. 2016)) 
(iv) Available GAL4 drivers to restrict 
expression to post-mitotic adult neurons 
(e.g. Rh1)(Chouhan et al. 2016) 
(i) GMR drives expression during photoreceptor 
development; noted degeneration due to 
developmental tau expression 
(ii) Not all driver lines are specific to one cell-
type (e.g. GMR drives expression in glia and 




(v) Available GAL4 drivers to spatially 
restrict expression to specific cell-types 
(e.g. Rh1, R7 and sev) 
 






(i) Can target MBs to study effects of tau 
on learning and memory in adult flies 
(Mershin et al. 2004) 
(ii) Driver lines that express only in adult 
post-mitotic cells of MB are available 
(e.g. c492, c772) (Mershin et al. 2004)  
(iii) Observe tau-mediate 
neurodegeneration and dysfunction 
 
(i) Drivers such as elav are global and not 
specific to just the MBs, meaning one cannot 
rule out the effects of tau expression on other 
brain regions/circuits  
(ii) Some drivers induce expression during early 
neuronal development (e.g. elav); noted 












(i) Larval neuromuscular junction is a 
well-established model  
(ii)  Single cell resolution 
(iii) Easy to assay axon trafficking and 
synaptic bouton morphology (Mudher et 
al. 2004, Talmat-Amar et al. 2011) 
 (iv) Can perform electrophysiology to 
directly measure neuronal function (Chee 
et al. 2005) 
 
(i) Cannot examine age-dependent tau-
mediated phenotypes in larva 
 
b. Sensory neurons 
 
c161, e16E,  
R7 
 
(i) Can be used to examine toxicity in 
adult sensory neurons (Williams et al. 
2000, Sealey et al. 2017) 
(ii) Can be used to examine age-
dependent tau toxicity in the adult fly eye 
(e.g. R7) 
 
(i) Expression not specific to one particular type 









(i) Targeting expression to smaller 
groups of neurons with a common 
physiological property (Wu et al. 2013) 
(ii) See tangle pathology in dopaminergic 
neurons 
(i) Some driver lines produce more specific, 
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